secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jasper Therapeutics, Inc. (JSPR)
CIK:        0001788028
Form:       8-K
Filed at:   2025-01-08T23:59:59+00:00
Accession:  0001213900-25-001810
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jasper reports positive BEACON data: 240mg dose shows UAS7 drop of 26.6, 100% complete response at 8 weeks
--------------------------------------------------------------------------------

- Mean UAS7 change of -26.6 at 8 weeks in 240mg single-dose cohort (N=3); all patients achieved Complete Response (UAS7=0).
- Multiple dosing regimens ≥120mg showed UAS7 reduction >25 points; clinical responses as early as 1 week post-first dose.
- Serum tryptase reductions below lower limit of quantification observed; 100% of 240mg cohort at week 1.
- Favorable safety profile: no dose-limiting toxicities, infrequent low-grade c-Kit blockade events, no discontinuations.
- Registrational Phase 2b study in CSU expected to commence in second half of 2025; additional data by mid-2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1788028/000121390025001810/0001213900-25-001810-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1788028/000121390025001810/ea0227148-8k_jasper.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-001810

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer